요약정보
Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network.
- Resource Type
- Academic Journal
- Authors
- Zeng Z; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Fu J; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Clinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Science and Technology, Tongji University, Shanghai, China.; Cibulskis C; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Jhaveri A; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Gumbs C; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Das B; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland.; Sanchez-Espiridion B; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Janssens S; The Emmes Company, LLC, Rockville, Maryland.; Taing L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Wang J; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Clinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Science and Technology, Tongji University, Shanghai, China.; Lindsay J; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Vilimas T; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland.; Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Tokheim C; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Sahu A; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Jiang P; Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.; Yan C; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland.; Duose DY; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Cerami E; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Chen L; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland.; Cohen D; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Chen Q; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland.; Enos R; The Emmes Company, LLC, Rockville, Maryland.; Huang X; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Lee JJ; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Liu Y; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Neuberg DS; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Nguyen C; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland.; Patterson C; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Sarkar S; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Shukla S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts.; Tang M; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.; Tsuji J; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Uduman M; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Wang X; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Weirather JL; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Yu J; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Yu J; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Zhang J; Department of Thoracic/Head and Neck Medical Oncology and Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Zhang J; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Meerzaman D; Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland.; Thurin M; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.; Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Karlovich C; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland.; Gabriel SB; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Liu XS; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts. cwu@partners.org xsliu@ds.dfci.harvard.edu.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts.; Wu CJ; Broad Institute of MIT and Harvard, Cambridge, Massachusetts. cwu@partners.org xsliu@ds.dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
- Source
- Publisher:
The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN:10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE - Subject
- Language
- English